A Phase 4 interventional study of Fluticasone furoate/umeclidinium bromide/vilanterol trifenatate and Inhaled corticosteroids/long-acting beta-2 agonists in Asthma, sponsored by GlaxoSmithKline. Active, not recruiting at 117 sites in 8 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-06.
Sponsored by GlaxoSmithKline · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 40 studies testing fluticasone furoate in Asthma — none open to participants now, 3 under way, 2 of them phase 3. fluticasone furoate · Asthma.
Among the 40 studies testing fluticasone furoate in Asthma, this one is the 2nd largest by enrollment, is the only one that started in 2024, is one of 6 in phase 4, and was the 40th registered.
4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.
Browse Asthma studies →None of the 40 studies testing fluticasone furoate in Asthma is open now. The open studies under Asthma, anywhere →
fluticasone furoate: first FDA approval 2007 (FLONASE SENSIMIST ALLERGY RELIEF), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →
Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
40 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 1 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,358 is above the median of 79 across 3,344 interventional studies indexed under Asthma.
Median enrollment 102 across the 40 interventional studies. Of the 35 that completed or were terminated, 22 (63%) have results posted.
This tab as a report to print or save as PDF → With an account.
36 of 40 have an industry lead sponsor. The 4 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
262 studies in Asthma by GlaxoSmithKline: 7 open now, 12 under way, 7 of them phase 3. Of 240 finished, 132 (55%) have results posted.
Among the 262 studies in Asthma by GlaxoSmithKline, this one is the 9th largest by enrollment of the 238 interventional ones that give a count, is one of 8 that started in 2024, is one of 53 in phase 4, reaches primary completion later than 0 of the 11 other live ones, and was the 249th registered.
GlaxoSmithKline’s Asthma studies by the year they started, since 1999.
1 of the studies testing fluticasone furoate in Asthma that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05757102Phase 3GlaxoSmithKlineA Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma | 2027-01-26 |
Add it to your calendar (.ics) → With an account.
Among the 40 studies testing fluticasone furoate in Asthma, from their registry updates:
Among GlaxoSmithKline’s 262 in Asthma:
This tab as a report to print or save as PDF → With an account.
The goal of this study is to assess and compare the effectiveness of fluticasone furoate/umeclidinium bromide/vilanterol trifenatate (FF/UMEC/VI) with inhaled corticosteroids/long-acting beta-2 agonists (ICS/LABA) in adult participants with uncontrolled asthma
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participants are eligible to be included in the study only if all of the following criteria apply:
Participants who are either:
Exclusion Criteria:
Participants are excluded from the study if any of the following criteria apply:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with uncontrolled asthma were randomized to receive a once-daily (QD) fixed-dose combination of 100 microgram (mcg) fluticasone furoate (FF), 62.5 mcg umeclidinium (UMEC), and 25 mcg vilanterol (VI) via the Ellipta dry powder inhaler (DPI) for up to 24 weeks. At the discretion of the investigator, a subset of participants received the high-dose ICS-containing therapy, FF/UMEC/VI 200/62.5/25 instead. At any time during the study (post-randomization), participants were escalated to receive FF/UMEC/VI 200/62.5/25 mcg if their asthma control worsened significantly, defined as an increase in Asthma Control Questionnaire (ACQ-7) total score of \>0.5 from baseline and the physician determines increased Inhaled Corticosteroid \[ICS\] is ethically necessary.
Drug: Fluticasone furoate/umeclidinium bromide/vilanterol trifenatate
Participants with uncontrolled asthma were randomized to receive Inhaled Corticosteroid \[ICS\]/Long-acting beta-2 agonist \[LABA\] based on usual care as per the country specific regulatory labels up to 24 weeks. At the discretion of the investigator, a subset of participants received high-dose ICS/LABA. At any time during the study (post-randomization), participants were escalated to receive high dose ICS/LABA if their asthma control worsened significantly, defined as an increase in ACQ-7 total score of \>0.5 from baseline and the physician determines increased ICS is ethically necessary.
Drug: Inhaled corticosteroids/long-acting beta-2 agonists
Drug pages: Fluticasone furoate · Umeclidinium bromide · Vilanterol trifenatate
Participants will receive FF/UMEC/VI
Participants will receive ICS/LABA
Change From Baseline (CFB) in Trough Forced Expiratory Volume in 1 Second (FEV1) at Week 24
FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Trough FEV1 on treatment is defined as the last FEV1 value obtained prior to the morning dose of investigational product. Spirometry was performed to assess FEV1. Baseline is defined as the last acceptable/borderline acceptable pre-dose FEV1 obtained at the Randomization Visit (Visit 2/Day 1). Change from Baseline was calculated by subtracting Baseline value from the post-dose visit (Week 24) value
Time frame: Baseline (Day 1) and at Week 24
Percentage of Participants Achieving Greater Than Equal to (>=) 0.5 Point Improvement (Decrease) From Baseline for the Asthma Control Questionnaire-7 (ACQ-7) at Week 24
The ACQ-7 measures 7 attributes of asthma control and consists of 5 symptom related questions (nocturnal awakening, symptoms on waking in the morning, activity limitation, shortness of breath, and wheeze) with response options ranging from 0 (no impairment/limitation) to 6 (total impairment/ limitation).ACQ-7 total score is the mean of the responses of the 7 items, ranges from 0 to 6. Higher score indicates poor control. A score of less than equal to (\<=)0.75 indicates well-controlled asthma, a score of between 0.75 and 1.5 indicates partially controlled asthma, and a score \>=1.5 indicates poorly controlled asthma. Greater than or equal to 0.5 point decrease from baseline suggests a clinically important change in asthma control. Baseline is defined as the last non-missing value prior to or on the prescription date of study intervention. Percentage values are rounded off.
Time frame: Baseline (Day 1) and at Week 24
Percentage of Participants Achieving the Composite Endpoint (Optimized) at Week 52
The 4-point composite endpoint is defined as meeting the following criteria: Change from baseline in trough FEV1 \>= 100 milliliter (mL) at Week 52, Controlled asthma based on ACQ-5 total score \<= 1.5 at Week 52, No severe asthma exacerbations over 52 weeks and oral corticosteroids (OCS)-free over 52 weeks
Time frame: Baseline (Day 1) and at Week 52
Change From Baseline in Trough Forced Expiratory Volume in 1 Second (FEV1) at Week 52
FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Trough FEV1 on treatment is defined as the last FEV1 value obtained prior to the morning dose of investigational product. Spirometry was performed to assess FEV1. Baseline is defined as the last acceptable/borderline acceptable pre-dose FEV1 obtained at the Randomization Visit (Visit 2/Day 1).
Time frame: Baseline (Day 1) and at Week 52
Percentage of Participants With Change From Baseline in Trough FEV1 >= 100 mL at Week 24
FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Trough FEV1 on treatment is defined as the last FEV1 value obtained prior to the morning dose of investigational product. Spirometry was performed to assess FEV1. Baseline is defined as the last acceptable/borderline acceptable pre-dose FEV1 obtained at the Randomization Visit (Visit 2/Day 1). Change from Baseline was calculated by subtracting Baseline value from the post-dose visit (Week 24) value. Percentage values are rounded-off.
Time frame: Baseline (Day 1) and at Week 24
Percentage of Participants With Change From Baseline in Trough FEV1 >= 100 mL at Week 52
FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Trough FEV1 on treatment is defined as the last FEV1 value obtained prior to the morning dose of investigational product. Spirometry was performed to assess FEV1. Baseline is defined as the last acceptable/borderline acceptable pre-dose FEV1 obtained at the Randomization Visit (Visit 2/Day 1).
Time frame: Baseline (Day 1) and at Week 52
Percentage of Participants With Change From Baseline in Trough FEV1 >= 0 mL at Week 24
FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Trough FEV1 on treatment is defined as the last FEV1 value obtained prior to the morning dose of investigational product. Spirometry was performed to assess FEV1. Baseline is defined as the last acceptable/borderline acceptable pre-dose FEV1 obtained at the Randomization Visit (Visit 2/Day 1). Change from Baseline was calculated by subtracting Baseline value from the post-dose visit (Week 24) value. Percentage values are rounded-off.
Time frame: Baseline (Day 1) and at Week 24
Percentage of Participants With Change From Baseline in Trough FEV1 >= 0 mL at Week 52
FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Trough FEV1 on treatment is defined as the last FEV1 value obtained prior to the morning dose of investigational product. Spirometry was performed to assess FEV1. Baseline is defined as the last acceptable/borderline acceptable pre-dose FEV1 obtained at the Randomization Visit (Visit 2/Day 1).
Time frame: Baseline (Day 1) and at Week 52
Percentage of Participants Achieving >= 0.5 Point Improvement (Decrease) From Baseline for the ACQ-7 Score at Week 52
The ACQ-7 measures 7 attributes of asthma control and consists of 5 symptom related questions (nocturnal awakening, symptoms on waking in the morning, activity limitation, shortness of breath and wheeze) with response options ranging from zero (no impairment/limitation) to 6 (total impairment/ limitation). ACQ-7 total score is the mean of the responses of the 7 items, ranges from 0 to 6. Higher score indicates poor control. A score of less than equal to (\<=) 0.75 indicates well-controlled asthma, a score of between 0.75 and 1.5 indicates partially controlled asthma, and a score \>= 1.5 indicates poorly controlled asthma. Greater than or equal to 0.5 point decrease from baseline suggests a clinically important change in asthma control. Baseline is defined as the last non-missing value prior to or on the prescription date of study intervention.
Time frame: Baseline (Day 1) and at Week 52
Percentage of Participants Achieving >=0.5 Point Improvement (Decrease) From Baseline for the ACQ-6 Score at Week 24
The ACQ-6 is a shortened version of the ACQ-7 derived by removing one element (lung function element) from the original version. ACQ-6 consists of 6 questions scored from zero (no impairment/limitation) to six (total impairment/ limitation). Higher scores indicate greater impairment. Mean scores of \<=0.75 indicate well-controlled asthma, scores between 0.75 and 1.5 indicate partially controlled asthma, and scores \>=1.5 indicate poorly controlled asthma. A decrease in ACQ-6 score from Baseline indicates an improvement in asthma control, and individual changes of at least 0.5 are considered clinically meaningful. Baseline is defined as the last non-missing value prior to or on the prescription date of study intervention. Percentage values are rounded off.
Time frame: Baseline (Day 1) and at Week 24
Percentage of Participants Achieving >=0.5 Point Improvement (Decrease) From Baseline for the ACQ-6 Score at Week 52
The ACQ-6 is a shortened version of the ACQ-7 derived by removing one element (lung function element) from the original version. ACQ-6 consists of 6 questions scored from zero (no impairment/limitation) to six (total impairment/ limitation). Higher scores indicate greater impairment. Mean scores of \<=0.75 indicate well-controlled asthma, scores between 0.75 and 1.5 indicate partially controlled asthma, and scores \>=1.5 indicate poorly controlled asthma. A decrease in ACQ-6 score from Baseline indicates an improvement in asthma control, and individual changes of at least 0.5 are considered clinically meaningful. Baseline is defined as the last non-missing value prior to or on the prescription date of study intervention.
Time frame: Baseline (Day 1) and at Week 52
Percentage of Participants Achieving >=0.5 Point Improvement (Decrease) From Baseline for the ACQ-5 Score at Week 24
The ACQ-5 is a five-item questionnaire designed to be self-completed by the participants to assess the most common asthma symptoms. The 5 questions enquired to recall how their asthma had been during the previous week and to respond about the frequency and/or severity of symptoms (nocturnal awakening, symptoms on waking in the morning, activity limitation, shortness of breath and wheeze). The overall ACQ-5 response option is the mean score of all 5 questions representing 0=no impairment/limitation and 6=total impairment/ limitation. Higher scores indicated more limitations and lower scores indicated better asthma control. Higher score indicates worse symptoms. Greater than or equal to 0.5 point decrease from baseline suggests a clinically important change in asthma control. Baseline is defined as the last non-missing value prior to or on the prescription date of study intervention. Percentage values are rounded-off.
Time frame: Baseline (Day 1) and at Week 24
Percentage of Participants Achieving >=0.5 Point Improvement (Decrease) From Baseline for the ACQ-5 at Week 52
The ACQ-5 is a five-item questionnaire designed to be self-completed by the participants to assess the most common asthma symptoms. The 5 questions enquired to recall how their asthma had been during the previous week and to respond about the frequency and/or severity of symptoms (nocturnal awakening, symptoms on waking in the morning, activity limitation, shortness of breath and wheeze). The overall ACQ-5 response option is the mean score of all 5 questions representing 0=no impairment/limitation and 6=total impairment/ limitation. Higher scores indicated more limitations and lower scores with better asthma control. Higher score indicates worse symptoms. Greater than or equal to 0.5 point decrease from Baseline suggests a clinically important change in asthma control. Baseline is defined as the last non-missing value prior to or on the prescription date of study intervention.
Time frame: Baseline (Day 1) and at Week 52
Change From Baseline (CFB) in the ACQ-7 Total Score at Week 24
The ACQ-7 measures 7 attributes of asthma control and consists of 5 symptom related questions (nocturnal awakening, symptoms on waking in the morning, activity limitation, shortness of breath, and wheeze) with response options ranging from 0 (no impairment/limitation) to 6 (total impairment/ limitation). ACQ-7 total score is the mean of the responses of the 7 items, ranges from 0 to 6. Higher score indicates poor control. A score of less than equal to 0.75 indicates well-controlled asthma, a score of between 0.75 and 1.5 indicates partially controlled asthma, and a score \>=1.5 indicates poorly controlled asthma. Baseline is defined as the last non-missing value prior to or on the prescription date of study intervention. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit (Week 24) value
Time frame: Baseline (Day 1) and at Week 24
Change From Baseline (CFB) in the ACQ-7 Total Score at Week 52
The ACQ-7 measures 7 attributes of asthma control and consists of 5 symptom related questions (nocturnal awakening, symptoms on waking in the morning, activity limitation, shortness of breath, and wheeze) with response options ranging from 0 (no impairment/limitation) to 6 (total impairment/ limitation). ACQ-7 total score is the mean of the responses of the 7 items, ranges from 0 to 6. Higher score indicates poor control. A score of less than equal to 0.75 indicates well-controlled asthma, a score of between 0.75 and 1.5 indicates partially controlled asthma, and a score \>=1.5 indicates poorly controlled asthma. Baseline is defined as the last non-missing value prior to or on the prescription date of study intervention.
Time frame: Baseline (Day 1) and at Week 52
Change From Baseline (CFB) in the ACQ-6 Total Score at Week 24
The ACQ-6 is a shortened version of the ACQ-7 derived by removing one element (lung function element) from the original version. ACQ-6 consists of 6 questions scored from zero (no impairment/limitation) to six (total impairment/ limitation). Higher scores indicate greater impairment. Mean scores of \<=0.75 indicate well-controlled asthma, scores between 0.75 and 1.5 indicate partially controlled asthma, and scores \>=1.5 indicate poorly controlled asthma. Baseline is defined as the last non-missing value prior to or on the prescription date of study intervention. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit (Week 24) value.
Time frame: Baseline (Day 1) and at Week 24
Change From Baseline (CFB) in the ACQ-6 Total Score at Week 52
The ACQ-6 is a shortened version of the ACQ-7 derived by removing one element (lung function element) from the original version. ACQ-6 consists of 6 questions scored from zero (no impairment/limitation) to six (total impairment/ limitation). Higher scores indicate greater impairment. Mean scores of \<=0.75 indicate well-controlled asthma, scores between 0.75 and 1.5 indicate partially controlled asthma, and scores \>=1.5 indicate poorly controlled asthma. Baseline is defined as the last non-missing value prior to or on the prescription date of study intervention.
Time frame: Baseline (Day 1) and at Week 52
Change From Baseline (CFB) in the ACQ-5 Total Score at Week 24
The ACQ-5 is a five-item questionnaire designed to be self-completed by the participants to assess the most common asthma symptoms. The 5 questions enquired to recall how their asthma had been during the previous week and to respond about the frequency and/or severity of symptoms (nocturnal awakening, symptoms on waking in the morning, activity limitation, shortness of breath and wheeze). The overall ACQ-5 response option is the mean score of all 5 questions representing 0=no impairment/limitation and 6=total impairment/limitation. Higher scores indicated more limitations and lower scores indicated better asthma control. Higher score indicates worse symptoms. Baseline is defined as the last non-missing value prior to or on the prescription date of study intervention. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit (Week 24) value.
Time frame: Baseline (Day 1) and at Week 24
Change From Baseline (CFB) in the ACQ-5 Total Score at Week 52
The ACQ-5 is a five-item questionnaire designed to be self-completed by the participants to assess the most common asthma symptoms. The 5 questions enquired to recall how their asthma had been during the previous week and to respond about the frequency and/or severity of symptoms (nocturnal awakening, symptoms on waking in the morning, activity limitation, shortness of breath and wheeze). The overall ACQ-5 response option is the mean score of all 5 questions representing 0=no impairment/limitation and 6=total impairment/limitation. Higher scores indicated more limitations and lower scores indicated better asthma control. Higher score indicates worse symptoms. Baseline is defined as the last non-missing value prior to or on the prescription date of study intervention.
Time frame: Baseline (Day 1) and at Week 52
Change From Baseline (CFB) in the Asthma Control Test (ACT) Score at Week 24
The ACT is a validated self-completed questionnaire utilizing 5 questions to assess asthma control on a 5-point categorical scale ranging from 1 (not controlled at all) to 5 (completely controlled) with higher scores indicating better control. Total ACT score is calculated as the sum of the scores from the 5 questions and can range from 5 to 25, with higher scores indicating better control. An ACT total score of 5 to 15 suggests that the participant's asthma is poorly controlled, a score of 16 to 19 suggests that the participant's asthma is somewhat controlled, and a score of 20 to 25 suggests that the participant's asthma is well controlled. Baseline is defined as the last non-missing value prior to or on the prescription date of study intervention. CFB was calculated by subtracting Baseline value from the post-dose visit (Week 24) value.
Time frame: Baseline (Day 1) and at Week 24
Change From Baseline (CFB) in the Asthma Control Test (ACT) Score at Week 52
The ACT is a validated self-completed questionnaire utilizing 5 questions to assess asthma control on a 5-point categorical scale ranging from 1 (not controlled at all) to 5 (completely controlled) with higher scores indicating better control. Total ACT score is calculated as the sum of the scores from the 5 questions and can range from 5 to 25, with higher scores indicating better control. An ACT total score of 5 to 15 suggests that the participant's asthma is poorly controlled, a score of 16-to 19 suggests that the participant's asthma is somewhat controlled, and a score of 20 to 25 suggests that the participant's asthma is well controlled. Baseline is defined as the last non-missing value prior to or on the prescription date of study intervention.
Time frame: Baseline (Day 1) and at Week 52
Percentage of Participants Achieving the Composite Endpoint (Optimized) Subset on Participants Receiving ICS/LABA Prior to Randomization at Week 52
The 4-point composite endpoint is defined as meeting the following criteria: 1. Change from baseline in trough FEV1 ≥ 100 mL at Week 52; 2. Controlled asthma based on ACQ-5 total score \<= 1.5 at Week 52; 3. No severe asthma exacerbations over 52 weeks; 4. OCS-free over 52 weeks. Subset on participants receiving ICS/LABA prior to randomization.
Time frame: Baseline (Day 1) and at Week 52
Percentage of Participants Achieving the Composite Endpoint (Optimized) Subset on Participants Receiving no Treatment Prior to Randomization at Week 52
The 4-point composite endpoint is defined as meeting the following criteria: 1. Change from baseline in trough FEV1 ≥ 100 mL at Week 52; 2. Controlled asthma based on ACQ-5 total score \<= 1.5 at Week 52; 3. No severe asthma exacerbations over 52 weeks; 4. OCS-free over 52 weeks. Subset on participants receiving no treatment prior to randomization (no ICS-containing therapy within the 3 months prior to randomization).
Time frame: Baseline (Day 1) and at Week 52
Change From Baseline (CFB) in the Asthma Quality of Life Questionnaire (AQLQ-12) Total Score at Week 24
AQLQ-12 is a disease-specific, self-administered quality of life questionnaire used to evaluate impact of asthma treatments on quality of life of asthma sufferers. AQLQ-12 has 32 items in 4 domains: activity limitation (11 items), symptoms (12 items), emotional function (5 items), environmental stimuli (4 items). For 32 items on questionnaire, response format consists of a 7-point scale, where 1 indicates "total impairment" and 7 indicates "no impairment." AQLQ-12 total score is defined as average of scores from all 32 questions; thus, total score ranges from 1="total impairment" to 7=indicates "no impairment". Higher score is better asthma-related health-related quality of life. Baseline is last non-missing value prior to or on prescription date of study intervention. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit (Week 24) value.
Time frame: Baseline (Day 1) and at Week 24
Change From Baseline (CFB) in the Asthma Quality of Life Questionnaire (AQLQ-12) Total Score at Week 52
AQLQ-12 is a disease-specific, self-administered quality of life questionnaire to evaluate impact of asthma treatments on quality of life of asthma sufferers. AQLQ-12 has 32 items in 4 domains: activity limitation (11 items), symptoms (12 items), emotional function (5 items), environmental stimuli (4 items). For 32 items on questionnaire, response format consists of a 7-point scale, where a value of 1 indicates "total impairment" and a value of 7 indicates "no impairment." AQLQ-12 total score is defined as average of scores from all 32 questions; thus, total score ranges from 1="total impairment" to 7="no impairment". Higher score is better asthma-related health-related quality of life. Baseline is last non-missing value prior to or on prescription date of study intervention.
Time frame: Baseline (Day 1) and at Week 52
Change From Baseline (CFB) in the Asthma Quality of Life Questionnaire (AQLQ-12) Domain Score at Week 24
AQLQ-12 is a disease-specific, self-administered quality of life questionnaire used to evaluate impact of asthma treatments on quality of life of asthma sufferers. AQLQ-12 has 32 items in 4 domains: symptoms (12 items), environmental stimuli (4 items), activity limitation (11 items), emotional function (5 items). For 32 items on questionnaire, response format consists of a 7-point scale, where 1 indicates "total impairment" and 7 indicates "no impairment." AQLQ-12 each domain score total score is defined as average of scores from all the 32 questions from the respective domain; thus, each domain total score ranges from 1="total impairment" to 7=indicates "no impairment". Higher score is better asthma-related health-related quality of life. Each domain score is the mean of item scores within that domain. Baseline is last non-missing value prior to or on prescription date of study intervention. CFB was calculated by subtracting Baseline value from the post-dose visit (Week 24) value.
Time frame: Baseline (Day 1) and at Week 24
Change From Baseline (CFB) in the Asthma Quality of Life Questionnaire (AQLQ-12) Domain Score at Week 52
AQLQ-12 is a disease-specific, self-administered quality of life questionnaire used to evaluate impact of asthma treatments on quality of life of asthma sufferers. AQLQ-12 has 32 items in 4 domains: symptoms (12 items), environmental stimuli (4 items), activity limitation (11 items), emotional function (5 items). For 32 items on questionnaire, response format consists of a 7-point scale, where 1 indicates "total impairment" and 7 indicates "no impairment." AQLQ-12 each domain score total score is defined as average of scores from all the 32 questions from the respective domain; thus, each domain total score ranges from 1="total impairment" to 7=indicates "no impairment". Higher score is better asthma-related health-related quality of life. Each domain score is the mean of item scores within that domain. Baseline is last non-missing value prior to or on prescription date of study intervention.
Time frame: Baseline (Day 1) and at Week 52
Change From Baseline (CFB) in the Four Domains of the Asthma-specific Adaptation of the Work Productivity and Activity Impairment (WPAI) Questionnaire at Week 24
WPAI questionnaire measures impact due to poor health due to asthma on work and regular activities, yielding 4 percentage-based impairment scores, each ranges from 0 to 100%. Higher values=greater impairment and less productivity. Calculation of these 4 scores are as follows: 1. Work time missed due to health (Absenteeism)=hours missed due to health divided by (hours missed due to health+hours missed for other reasons+hours actually worked) \*100. 2. Impairment while working due to health (Presenteeism) =Question (Q)5 score (from 0 to 10) divided by 10\*100. 3. Overall work impairment due to health =Absenteeism+(1-Absenteeism fraction)\*Presenteeism. 4. Activity impairment due to health =Q6 score (from 0 to 10) divided by 10\*100. Baseline is last non-missing value prior to or on prescription date of study intervention. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit (Week 24) value.
Time frame: Baseline (Day 1) and at Week 24
Change From Baseline in the Four Domains of the Asthma-specific Adaptation of the Work Productivity and Activity Impairment Questionnaire at Week 52
WPAI questionnaire measures impact due to poor health due to asthma on work and regular activities, yielding 4 percentage-based impairment scores, each ranges from 0 to 100%. Higher value=greater impairment and less productivity. Calculation of these 4 scores are as follows: 1. Work time missed due to health (Absenteeism) =hours missed due to health divided by (hours missed due to health+hours missed for other reasons+hours actually worked) \*100. 2. Impairment while working due to health (Presenteeism) =Question (Q)5 score (from 0 to 10) divided by 10\*100. 3. Overall work impairment due to health =Absenteeism+(1-Absenteeism fraction)\*Presenteeism. 4. Activity impairment due to health =Q6 score (from 0 to 10) divided by 10\*100. Baseline is last non-missing value prior to or on prescription date of study intervention.
Time frame: Baseline (Day 1) and at Week 52
Change From Baseline in Trough Forced Expiratory Volume in 1 Second (FEV1) at Week 24 Among Participants on ICS/LABA Prior to Randomization
FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Trough FEV1 on treatment is defined as the last FEV1 value obtained prior to the morning dose of investigational product. Spirometry was performed to assess FEV1. Baseline is defined as the last acceptable/borderline acceptable pre-dose FEV1 obtained at the Randomization Visit (Visit 2/Day 1). Per Protocol the study's subgroup analysis design, the analysis for this endpoint at Week 24 will be performed based on results from the composite (optimized) endpoint's Week 52 analysis. The pending results are expected to be available within 12 months of End of Study (EOS) date.
Time frame: Baseline (Day 1) and Week 24
Percentage of Participants Achieving >=0.5 Points Improvement (Decrease) From Baseline for ACQ-7 at Week 24 Among Participants on ICS/LABA Prior to Randomization
The ACQ-7 measures 7 attributes of asthma control \& includes 5 symptom questions (nocturnal awakening,symptoms on waking in morning,activity limitation,shortness of breath \& wheeze). Responses ranges from 0 (no impairment/limitation) to 6 (total impairment/ limitation). ACQ-7 total score is mean of the responses of 7 items, ranges from 0 to 6. Higher score = poor control. A score of \<= 0.75 is well-controlled asthma; a score between 0.75 and 1.5 is partially controlled asthma \& a score \>= 1.5 is poorly controlled asthma. \>= 0.5 point decrease from baseline is clinically important change in asthma control. Baseline is last non-missing value prior to or on the prescription date of study intervention. Per Protocol study's subgroup analysis design, analysis for this endpoint at Week 24 will be performed based on results from composite (optimized) endpoint's Week 52 analysis. The pending results are expected to be available within 12 months of EOS date.
Time frame: Baseline (Day 1) and at Week 24
Percentage of Participants Achieving >=0.5 Points Improvement (Decrease) From Baseline for ACQ-7 at Week 52 Among Participants on ICS/LABA Prior to Randomization
The ACQ-7 measures 7 attributes of asthma control \& includes 5 symptom questions (nocturnal awakening,symptoms on waking in the morning,activity limitation,shortness of breath \& wheeze). Responses ranges from 0 (no impairment/limitation) to 6 (total impairment/ limitation). ACQ-7 total score is mean of the responses of the 7 items, ranges from 0 to 6. Higher score = poor control. A score of \<= 0.75 is well-controlled asthma; a score between 0.75 and 1.5 is partially controlled asthma \& a score \>= 1.5 is poorly controlled asthma. \>= 0.5 point decrease from baseline is clinically important change in asthma control. Baseline is last non-missing value prior to or on the prescription date of study intervention.
Time frame: Baseline (Day 1) and at Week 52
Change From Baseline in the ACQ-7 Total Score at Week 24 Among Participants on ICS/LABA Prior to Randomization
The ACQ-7 measures 7 attributes of asthma control and consists of 5 symptom related questions with response options ranging from 0 (no impairment/limitation) to 6 (total impairment/ limitation). ACQ-7 total score is mean of responses of the 7 items, ranges from 0 to 6. Higher score indicates poor control. A score of less than equal to 0.75 indicates well-controlled asthma, a score between 0.75 and 1.5 indicates partially controlled asthma, and a score \>=1.5 indicates poorly controlled asthma. Baseline is defined as last non-missing value prior to or on prescription date of study intervention. Per Protocol the study's subgroup analysis design, the analysis for this endpoint at Week 24 will be performed based on results from the composite (optimized) endpoint's Week 52 analysis. The pending results are expected to be available within 12 months of End of Study date.
Time frame: Baseline (Day 1) and at Week 24
Change From Baseline (CFB) in the ACQ-7 Total Score at Week 52 Among Participants on ICS/LABA Prior to Randomization
The ACQ-7 measures 7 attributes of asthma control and consists of 5 symptom related questions (nocturnal awakening, symptoms on waking in the morning, activity limitation, shortness of breath, and wheeze) with response options ranging from 0 (no impairment/limitation) to 6 (total impairment/ limitation). ACQ-7 total score is the mean of the responses of the 7 items, ranges from 0 to 6. Higher score indicates poor control. A score of less than equal to 0.75 indicates well-controlled asthma, a score between 0.75 and 1.5 indicates partially controlled asthma, and a score \>=1.5 indicates poorly controlled asthma. Baseline is defined as the last non-missing value prior to or on the prescription date of study intervention.
Time frame: Baseline (Day 1) and at Week 52
Change From Baseline in Trough Forced Expiratory Volume in 1 Second (FEV1) at Week 24 for Participants With no Treatment Prior to Randomization
FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Trough FEV1 on treatment is defined as the last FEV1 value obtained prior to the morning dose of investigational product. Spirometry was performed to assess FEV1. Baseline is defined as the last acceptable/borderline acceptable pre-dose FEV1 obtained at the Randomization Visit (Visit 2/Day 1). Per Protocol the study's subgroup analysis design, the analysis for this endpoint at Week 24 will be performed based on results from the composite (optimized) endpoint's Week 52 analysis. The pending results are expected to be available within 12 months of End of Study date.
Time frame: Baseline (Day 1) and Week 24
Percentage of Participants Achieving >=0.5 Points Improvement (Decrease) From Baseline for ACQ-7 at Week 24 for Participants With no Treatment Prior to Randomization.
The ACQ-7 measures 7 attributes of asthma control and consists of 5 symptom related questions (nocturnal awakening, symptoms on waking in the morning, activity limitation, shortness of breath and wheeze) with response options ranging from zero (no impairment/limitation) to 6 (total impairment/ limitation). A score of \<=0.75 indicates well-controlled asthma and a score \>=1.5 indicates poorly controlled asthma. \>= 0.5 point decrease from baseline is clinically important change in asthma control. Baseline is defined as the last non-missing value prior to or on the prescription date of study intervention. Per Protocol the study's subgroup analysis design, the analysis for this endpoint at Week 24 will be performed based on results from the composite (optimized) endpoint's Week 52 analysis. The pending results are expected to be available within 12 months of End of Study date.
Time frame: Baseline (Day 1) and at Week 24
Percentage of Participants Achieving >=0.5 Points Improvement (Decrease) From Baseline for ACQ-7 at Week 52 for Participants With no Treatment Prior to Randomization
The ACQ-7 measures 7 attributes of asthma control and consists of 5 symptom related questions (nocturnal awakening, symptoms on waking in the morning, activity limitation, shortness of breath and wheeze). Response ranges from 0 (no impairment/limitation) to 6 (total impairment/ limitation). ACQ-7 total score is mean of the responses of 7 items, ranges from 0 to 6. Higher score = poor control. A score of \<=0.75 indicates is well-controlled asthma; and a score \>=1.5 indicates poorly controlled asthma. Baseline is defined as the last non-missing value prior to or on the prescription date of study intervention.
Time frame: Baseline (Day 1) and at Week 52
Change From Baseline (CFB) in the ACQ-7 Total Score at Week 24 for Participants With no Treatment Prior to Randomization
The ACQ-7 measures 7 attributes of asthma control and consists of 5 symptom related questions (nocturnal awakening, symptoms on waking in the morning, activity limitation, shortness of breath and wheeze) with response options ranging from zero (no impairment/limitation) to 6 (total impairment/ limitation). A score of less than equal to 0.75 indicates well-controlled asthma, a score between 0.75 and 1.5 indicates partially controlled asthma, and a score \>=1.5 indicates poorly controlled asthma. A change of 0.5 in score suggests a clinically important change in asthma control. Baseline is defined as the last non-missing value prior to or on the prescription date of study intervention. Per Protocol the study's subgroup analysis design, the analysis for this endpoint at Week 24 will be performed based on results from the composite (optimized) endpoint's Week 52 analysis. The pending results are expected to be available within 12 months of End of Study date.
Time frame: Baseline (Day 1) and at Week 24
Change From Baseline (CFB) in the ACQ-7 Total Score at Week 52 for Participants With no Treatment Prior to Randomization
The ACQ-7 measures 7 attributes of asthma control and consists of 5 symptom related questions (nocturnal awakening, symptoms on waking in the morning, activity limitation, shortness of breath and wheeze) with response options ranging from zero (no impairment/limitation) to 6 (total impairment/ limitation). A score of less than equal to 0.75 indicates well-controlled asthma, a score of between 0.75 and 1.5 indicates partially controlled asthma, and a score \>=1.5 indicates poorly controlled asthma. Baseline is defined as the last non-missing value prior to or on the prescription date of study intervention.
Time frame: Baseline (Day 1) and at Week 52
| Milestone | Fluticasone Furoate [FF]/ Umeclidinium [UMEC]/ Vilanterol [VI] | Inhaled Corticosteroid [ICS]/Long-acting Beta-2 Agonist [LABA] |
|---|---|---|
| Started | 682 | 676 |
| Safety analysis set (saf)- modified 1 | 631 | 605 |
| Full analysis set - modified 1 | 619 | 617 |
| Completed | 42 | 38 |
| Not completed | 640 | 638 |
| Withdrew: Other | 1 | 2 |
| Withdrew: Withdrawal by subject | 22 | 22 |
| Withdrew: Site closed | 15 | 17 |
| Withdrew: Protocol violation | 1 | 0 |
| Withdrew: Physician decision | 2 | 0 |
| Withdrew: Lost to follow-up | 17 | 25 |
| Withdrew: Death | 0 | 1 |
| Withdrew: Adverse event | 1 | 1 |
| Withdrew: Excluded from fas-modified 1 due to data integrity concerns at the site | 59 | 54 |
| Withdrew: Randomized but not treated | 4 | 5 |
| Withdrew: Ongoing | 518 | 511 |
FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Trough FEV1 on treatment is defined as the last FEV1 value obtained prior to the morning dose of investigational product. Spirometry was performed to assess FEV1. Baseline is defined as the last acceptable/borderline acceptable pre-dose FEV1 obtained at the Randomization Visit (Visit 2/Day 1). Change from Baseline was calculated by subtracting Baseline value from the post-dose visit (Week 24) value
| Liter (L) | Fluticasone Furoate [FF]/ Umeclidinium [UMEC] / Vilanterol [VI] | Inhaled Corticosteroid [ICS]/Long-acting Beta-2 Agonist [LABA] |
|---|---|---|
| Change From Baseline (CFB) in Trough Forced Expiratory Volume in 1 Second (FEV1) at Week 24 | 0.178 ± 0.0198 | 0.110 ± 0.0196 |
The ACQ-7 measures 7 attributes of asthma control and consists of 5 symptom related questions (nocturnal awakening, symptoms on waking in the morning, activity limitation, shortness of breath, and wheeze) with response options ranging from 0 (no impairment/limitation) to 6 (total impairment/ limitation).ACQ-7 total score is the mean of the responses of the 7 items, ranges from 0 to 6. Higher score indicates poor control. A score of less than equal to (\<=)0.75 indicates well-controlled asthma, a score of between 0.75 and 1.5 indicates partially controlled asthma, and a score \>=1.5 indicates poorly controlled asthma. Greater than or equal to 0.5 point decrease from baseline suggests a clinically important change in asthma control. Baseline is defined as the last non-missing value prior to or on the prescription date of study intervention. Percentage values are rounded off.
| Percentage of Participants | Fluticasone Furoate [FF]/ Umeclidinium [UMEC] / Vilanterol [VI] | Inhaled Corticosteroid [ICS]/Long-acting Beta-2 Agonist [LABA] |
|---|---|---|
| Percentage of Participants Achieving Greater Than Equal to (>=) 0.5 Point Improvement (Decrease) From Baseline for the Asthma Control Questionnaire-7 (ACQ-7) at Week 24 | 79 | 71.8 |
The 4-point composite endpoint is defined as meeting the following criteria: Change from baseline in trough FEV1 \>= 100 milliliter (mL) at Week 52, Controlled asthma based on ACQ-5 total score \<= 1.5 at Week 52, No severe asthma exacerbations over 52 weeks and oral corticosteroids (OCS)-free over 52 weeks
Results for this outcome have not been posted.
FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Trough FEV1 on treatment is defined as the last FEV1 value obtained prior to the morning dose of investigational product. Spirometry was performed to assess FEV1. Baseline is defined as the last acceptable/borderline acceptable pre-dose FEV1 obtained at the Randomization Visit (Visit 2/Day 1).
Results for this outcome have not been posted.
FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Trough FEV1 on treatment is defined as the last FEV1 value obtained prior to the morning dose of investigational product. Spirometry was performed to assess FEV1. Baseline is defined as the last acceptable/borderline acceptable pre-dose FEV1 obtained at the Randomization Visit (Visit 2/Day 1). Change from Baseline was calculated by subtracting Baseline value from the post-dose visit (Week 24) value. Percentage values are rounded-off.
| Percentage of Participants | Fluticasone Furoate [FF]/ Umeclidinium [UMEC] / Vilanterol [VI] | Inhaled Corticosteroid [ICS]/Long-acting Beta-2 Agonist [LABA] |
|---|---|---|
| Percentage of Participants With Change From Baseline in Trough FEV1 >= 100 mL at Week 24 | 46.0 | 29.5 |
FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Trough FEV1 on treatment is defined as the last FEV1 value obtained prior to the morning dose of investigational product. Spirometry was performed to assess FEV1. Baseline is defined as the last acceptable/borderline acceptable pre-dose FEV1 obtained at the Randomization Visit (Visit 2/Day 1).
Results for this outcome have not been posted.
FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Trough FEV1 on treatment is defined as the last FEV1 value obtained prior to the morning dose of investigational product. Spirometry was performed to assess FEV1. Baseline is defined as the last acceptable/borderline acceptable pre-dose FEV1 obtained at the Randomization Visit (Visit 2/Day 1). Change from Baseline was calculated by subtracting Baseline value from the post-dose visit (Week 24) value. Percentage values are rounded-off.
| Percentage of Participants | Fluticasone Furoate [FF]/ Umeclidinium [UMEC] / Vilanterol [VI] | Inhaled Corticosteroid [ICS]/Long-acting Beta-2 Agonist [LABA] |
|---|---|---|
| Percentage of Participants With Change From Baseline in Trough FEV1 >= 0 mL at Week 24 | 65.9 | 51.5 |
FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Trough FEV1 on treatment is defined as the last FEV1 value obtained prior to the morning dose of investigational product. Spirometry was performed to assess FEV1. Baseline is defined as the last acceptable/borderline acceptable pre-dose FEV1 obtained at the Randomization Visit (Visit 2/Day 1).
Results for this outcome have not been posted.
The ACQ-7 measures 7 attributes of asthma control and consists of 5 symptom related questions (nocturnal awakening, symptoms on waking in the morning, activity limitation, shortness of breath and wheeze) with response options ranging from zero (no impairment/limitation) to 6 (total impairment/ limitation). ACQ-7 total score is the mean of the responses of the 7 items, ranges from 0 to 6. Higher score indicates poor control. A score of less than equal to (\<=) 0.75 indicates well-controlled asthma, a score of between 0.75 and 1.5 indicates partially controlled asthma, and a score \>= 1.5 indicates poorly controlled asthma. Greater than or equal to 0.5 point decrease from baseline suggests a clinically important change in asthma control. Baseline is defined as the last non-missing value prior to or on the prescription date of study intervention.
Results for this outcome have not been posted.
The ACQ-6 is a shortened version of the ACQ-7 derived by removing one element (lung function element) from the original version. ACQ-6 consists of 6 questions scored from zero (no impairment/limitation) to six (total impairment/ limitation). Higher scores indicate greater impairment. Mean scores of \<=0.75 indicate well-controlled asthma, scores between 0.75 and 1.5 indicate partially controlled asthma, and scores \>=1.5 indicate poorly controlled asthma. A decrease in ACQ-6 score from Baseline indicates an improvement in asthma control, and individual changes of at least 0.5 are considered clinically meaningful. Baseline is defined as the last non-missing value prior to or on the prescription date of study intervention. Percentage values are rounded off.
| Percentage of Participants | Fluticasone Furoate [FF]/ Umeclidinium [UMEC] / Vilanterol [VI] | Inhaled Corticosteroid [ICS]/Long-acting Beta-2 Agonist [LABA] |
|---|---|---|
| Percentage of Participants Achieving >=0.5 Point Improvement (Decrease) From Baseline for the ACQ-6 Score at Week 24 | 80.9 | 77.0 |
The ACQ-6 is a shortened version of the ACQ-7 derived by removing one element (lung function element) from the original version. ACQ-6 consists of 6 questions scored from zero (no impairment/limitation) to six (total impairment/ limitation). Higher scores indicate greater impairment. Mean scores of \<=0.75 indicate well-controlled asthma, scores between 0.75 and 1.5 indicate partially controlled asthma, and scores \>=1.5 indicate poorly controlled asthma. A decrease in ACQ-6 score from Baseline indicates an improvement in asthma control, and individual changes of at least 0.5 are considered clinically meaningful. Baseline is defined as the last non-missing value prior to or on the prescription date of study intervention.
Results for this outcome have not been posted.
The ACQ-5 is a five-item questionnaire designed to be self-completed by the participants to assess the most common asthma symptoms. The 5 questions enquired to recall how their asthma had been during the previous week and to respond about the frequency and/or severity of symptoms (nocturnal awakening, symptoms on waking in the morning, activity limitation, shortness of breath and wheeze). The overall ACQ-5 response option is the mean score of all 5 questions representing 0=no impairment/limitation and 6=total impairment/ limitation. Higher scores indicated more limitations and lower scores indicated better asthma control. Higher score indicates worse symptoms. Greater than or equal to 0.5 point decrease from baseline suggests a clinically important change in asthma control. Baseline is defined as the last non-missing value prior to or on the prescription date of study intervention. Percentage values are rounded-off.
| Percentage of Participants | Fluticasone Furoate [FF]/ Umeclidinium [UMEC] / Vilanterol [VI] | Inhaled Corticosteroid [ICS]/Long-acting Beta-2 Agonist [LABA] |
|---|---|---|
| Percentage of Participants Achieving >=0.5 Point Improvement (Decrease) From Baseline for the ACQ-5 Score at Week 24 | 80.1 | 75.2 |
The ACQ-5 is a five-item questionnaire designed to be self-completed by the participants to assess the most common asthma symptoms. The 5 questions enquired to recall how their asthma had been during the previous week and to respond about the frequency and/or severity of symptoms (nocturnal awakening, symptoms on waking in the morning, activity limitation, shortness of breath and wheeze). The overall ACQ-5 response option is the mean score of all 5 questions representing 0=no impairment/limitation and 6=total impairment/ limitation. Higher scores indicated more limitations and lower scores with better asthma control. Higher score indicates worse symptoms. Greater than or equal to 0.5 point decrease from Baseline suggests a clinically important change in asthma control. Baseline is defined as the last non-missing value prior to or on the prescription date of study intervention.
Results for this outcome have not been posted.
The ACQ-7 measures 7 attributes of asthma control and consists of 5 symptom related questions (nocturnal awakening, symptoms on waking in the morning, activity limitation, shortness of breath, and wheeze) with response options ranging from 0 (no impairment/limitation) to 6 (total impairment/ limitation). ACQ-7 total score is the mean of the responses of the 7 items, ranges from 0 to 6. Higher score indicates poor control. A score of less than equal to 0.75 indicates well-controlled asthma, a score of between 0.75 and 1.5 indicates partially controlled asthma, and a score \>=1.5 indicates poorly controlled asthma. Baseline is defined as the last non-missing value prior to or on the prescription date of study intervention. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit (Week 24) value
| Scores on a scale | Fluticasone Furoate [FF]/ Umeclidinium [UMEC] / Vilanterol [VI] | Inhaled Corticosteroid [ICS]/Long-acting Beta-2 Agonist [LABA] |
|---|---|---|
| Change From Baseline (CFB) in the ACQ-7 Total Score at Week 24 | -1.42 ± 0.054 | -1.25 ± 0.053 |
The ACQ-7 measures 7 attributes of asthma control and consists of 5 symptom related questions (nocturnal awakening, symptoms on waking in the morning, activity limitation, shortness of breath, and wheeze) with response options ranging from 0 (no impairment/limitation) to 6 (total impairment/ limitation). ACQ-7 total score is the mean of the responses of the 7 items, ranges from 0 to 6. Higher score indicates poor control. A score of less than equal to 0.75 indicates well-controlled asthma, a score of between 0.75 and 1.5 indicates partially controlled asthma, and a score \>=1.5 indicates poorly controlled asthma. Baseline is defined as the last non-missing value prior to or on the prescription date of study intervention.
Results for this outcome have not been posted.
The ACQ-6 is a shortened version of the ACQ-7 derived by removing one element (lung function element) from the original version. ACQ-6 consists of 6 questions scored from zero (no impairment/limitation) to six (total impairment/ limitation). Higher scores indicate greater impairment. Mean scores of \<=0.75 indicate well-controlled asthma, scores between 0.75 and 1.5 indicate partially controlled asthma, and scores \>=1.5 indicate poorly controlled asthma. Baseline is defined as the last non-missing value prior to or on the prescription date of study intervention. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit (Week 24) value.
| Scores on a scale | Fluticasone Furoate [FF]/ Umeclidinium [UMEC] / Vilanterol [VI] | Inhaled Corticosteroid [ICS]/Long-acting Beta-2 Agonist [LABA] |
|---|---|---|
| Change From Baseline (CFB) in the ACQ-6 Total Score at Week 24 | -1.58 ± 0.059 | -1.42 ± 0.058 |
The ACQ-6 is a shortened version of the ACQ-7 derived by removing one element (lung function element) from the original version. ACQ-6 consists of 6 questions scored from zero (no impairment/limitation) to six (total impairment/ limitation). Higher scores indicate greater impairment. Mean scores of \<=0.75 indicate well-controlled asthma, scores between 0.75 and 1.5 indicate partially controlled asthma, and scores \>=1.5 indicate poorly controlled asthma. Baseline is defined as the last non-missing value prior to or on the prescription date of study intervention.
Results for this outcome have not been posted.
The ACQ-5 is a five-item questionnaire designed to be self-completed by the participants to assess the most common asthma symptoms. The 5 questions enquired to recall how their asthma had been during the previous week and to respond about the frequency and/or severity of symptoms (nocturnal awakening, symptoms on waking in the morning, activity limitation, shortness of breath and wheeze). The overall ACQ-5 response option is the mean score of all 5 questions representing 0=no impairment/limitation and 6=total impairment/limitation. Higher scores indicated more limitations and lower scores indicated better asthma control. Higher score indicates worse symptoms. Baseline is defined as the last non-missing value prior to or on the prescription date of study intervention. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit (Week 24) value.
| Scores on a scale | Fluticasone Furoate [FF]/ Umeclidinium [UMEC] / Vilanterol [VI] | Inhaled Corticosteroid [ICS]/Long-acting Beta-2 Agonist [LABA] |
|---|---|---|
| Change From Baseline (CFB) in the ACQ-5 Total Score at Week 24 | -1.76 ± 0.064 | -1.60 ± 0.063 |
The ACQ-5 is a five-item questionnaire designed to be self-completed by the participants to assess the most common asthma symptoms. The 5 questions enquired to recall how their asthma had been during the previous week and to respond about the frequency and/or severity of symptoms (nocturnal awakening, symptoms on waking in the morning, activity limitation, shortness of breath and wheeze). The overall ACQ-5 response option is the mean score of all 5 questions representing 0=no impairment/limitation and 6=total impairment/limitation. Higher scores indicated more limitations and lower scores indicated better asthma control. Higher score indicates worse symptoms. Baseline is defined as the last non-missing value prior to or on the prescription date of study intervention.
Results for this outcome have not been posted.
The ACT is a validated self-completed questionnaire utilizing 5 questions to assess asthma control on a 5-point categorical scale ranging from 1 (not controlled at all) to 5 (completely controlled) with higher scores indicating better control. Total ACT score is calculated as the sum of the scores from the 5 questions and can range from 5 to 25, with higher scores indicating better control. An ACT total score of 5 to 15 suggests that the participant's asthma is poorly controlled, a score of 16 to 19 suggests that the participant's asthma is somewhat controlled, and a score of 20 to 25 suggests that the participant's asthma is well controlled. Baseline is defined as the last non-missing value prior to or on the prescription date of study intervention. CFB was calculated by subtracting Baseline value from the post-dose visit (Week 24) value.
| Scores on a scale | Fluticasone Furoate [FF]/ Umeclidinium [UMEC] / Vilanterol [VI] | Inhaled Corticosteroid [ICS]/Long-acting Beta-2 Agonist [LABA] |
|---|---|---|
| Change From Baseline (CFB) in the Asthma Control Test (ACT) Score at Week 24 | 5.92 ± 0.269 | 5.35 ± 0.265 |
The ACT is a validated self-completed questionnaire utilizing 5 questions to assess asthma control on a 5-point categorical scale ranging from 1 (not controlled at all) to 5 (completely controlled) with higher scores indicating better control. Total ACT score is calculated as the sum of the scores from the 5 questions and can range from 5 to 25, with higher scores indicating better control. An ACT total score of 5 to 15 suggests that the participant's asthma is poorly controlled, a score of 16-to 19 suggests that the participant's asthma is somewhat controlled, and a score of 20 to 25 suggests that the participant's asthma is well controlled. Baseline is defined as the last non-missing value prior to or on the prescription date of study intervention.
Results for this outcome have not been posted.
The 4-point composite endpoint is defined as meeting the following criteria: 1. Change from baseline in trough FEV1 ≥ 100 mL at Week 52; 2. Controlled asthma based on ACQ-5 total score \<= 1.5 at Week 52; 3. No severe asthma exacerbations over 52 weeks; 4. OCS-free over 52 weeks. Subset on participants receiving ICS/LABA prior to randomization.
Results for this outcome have not been posted.
The 4-point composite endpoint is defined as meeting the following criteria: 1. Change from baseline in trough FEV1 ≥ 100 mL at Week 52; 2. Controlled asthma based on ACQ-5 total score \<= 1.5 at Week 52; 3. No severe asthma exacerbations over 52 weeks; 4. OCS-free over 52 weeks. Subset on participants receiving no treatment prior to randomization (no ICS-containing therapy within the 3 months prior to randomization).
Results for this outcome have not been posted.
AQLQ-12 is a disease-specific, self-administered quality of life questionnaire used to evaluate impact of asthma treatments on quality of life of asthma sufferers. AQLQ-12 has 32 items in 4 domains: activity limitation (11 items), symptoms (12 items), emotional function (5 items), environmental stimuli (4 items). For 32 items on questionnaire, response format consists of a 7-point scale, where 1 indicates "total impairment" and 7 indicates "no impairment." AQLQ-12 total score is defined as average of scores from all 32 questions; thus, total score ranges from 1="total impairment" to 7=indicates "no impairment". Higher score is better asthma-related health-related quality of life. Baseline is last non-missing value prior to or on prescription date of study intervention. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit (Week 24) value.
| Scores on a Scale | Fluticasone Furoate [FF]/ Umeclidinium [UMEC] / Vilanterol [VI] | Inhaled Corticosteroid [ICS]/Long-acting Beta-2 Agonist [LABA] |
|---|---|---|
| Change From Baseline (CFB) in the Asthma Quality of Life Questionnaire (AQLQ-12) Total Score at Week 24 | 1.42 ± 0.069 | 1.27 ± 0.069 |
AQLQ-12 is a disease-specific, self-administered quality of life questionnaire to evaluate impact of asthma treatments on quality of life of asthma sufferers. AQLQ-12 has 32 items in 4 domains: activity limitation (11 items), symptoms (12 items), emotional function (5 items), environmental stimuli (4 items). For 32 items on questionnaire, response format consists of a 7-point scale, where a value of 1 indicates "total impairment" and a value of 7 indicates "no impairment." AQLQ-12 total score is defined as average of scores from all 32 questions; thus, total score ranges from 1="total impairment" to 7="no impairment". Higher score is better asthma-related health-related quality of life. Baseline is last non-missing value prior to or on prescription date of study intervention.
Results for this outcome have not been posted.
AQLQ-12 is a disease-specific, self-administered quality of life questionnaire used to evaluate impact of asthma treatments on quality of life of asthma sufferers. AQLQ-12 has 32 items in 4 domains: symptoms (12 items), environmental stimuli (4 items), activity limitation (11 items), emotional function (5 items). For 32 items on questionnaire, response format consists of a 7-point scale, where 1 indicates "total impairment" and 7 indicates "no impairment." AQLQ-12 each domain score total score is defined as average of scores from all the 32 questions from the respective domain; thus, each domain total score ranges from 1="total impairment" to 7=indicates "no impairment". Higher score is better asthma-related health-related quality of life. Each domain score is the mean of item scores within that domain. Baseline is last non-missing value prior to or on prescription date of study intervention. CFB was calculated by subtracting Baseline value from the post-dose visit (Week 24) value.
| Scores on a Scale | Fluticasone Furoate [FF]/ Umeclidinium [UMEC] / Vilanterol [VI] | Inhaled Corticosteroid [ICS]/Long-acting Beta-2 Agonist [LABA] |
|---|---|---|
| Symptoms | 1.61 ± 0.073 | 1.45 ± 0.072 |
| Environmental Stimuli | 1.17 ± 0.092 | 1.03 ± 0.091 |
| Activity Limitation | 1.32 ± 0.071 | 1.16 ± 0.071 |
| Emotional Function | 1.41 ± 0.087 | 1.28 ± 0.086 |
AQLQ-12 is a disease-specific, self-administered quality of life questionnaire used to evaluate impact of asthma treatments on quality of life of asthma sufferers. AQLQ-12 has 32 items in 4 domains: symptoms (12 items), environmental stimuli (4 items), activity limitation (11 items), emotional function (5 items). For 32 items on questionnaire, response format consists of a 7-point scale, where 1 indicates "total impairment" and 7 indicates "no impairment." AQLQ-12 each domain score total score is defined as average of scores from all the 32 questions from the respective domain; thus, each domain total score ranges from 1="total impairment" to 7=indicates "no impairment". Higher score is better asthma-related health-related quality of life. Each domain score is the mean of item scores within that domain. Baseline is last non-missing value prior to or on prescription date of study intervention.
Results for this outcome have not been posted.
WPAI questionnaire measures impact due to poor health due to asthma on work and regular activities, yielding 4 percentage-based impairment scores, each ranges from 0 to 100%. Higher values=greater impairment and less productivity. Calculation of these 4 scores are as follows: 1. Work time missed due to health (Absenteeism)=hours missed due to health divided by (hours missed due to health+hours missed for other reasons+hours actually worked) \*100. 2. Impairment while working due to health (Presenteeism) =Question (Q)5 score (from 0 to 10) divided by 10\*100. 3. Overall work impairment due to health =Absenteeism+(1-Absenteeism fraction)\*Presenteeism. 4. Activity impairment due to health =Q6 score (from 0 to 10) divided by 10\*100. Baseline is last non-missing value prior to or on prescription date of study intervention. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit (Week 24) value.
| Scores on a scale | Fluticasone Furoate [FF]/ Umeclidinium [UMEC] / Vilanterol [VI] | Inhaled Corticosteroid [ICS]/Long-acting Beta-2 Agonist [LABA] |
|---|---|---|
| Work time missed due to health | -5.45 ± 0.895 | -4.80 ± 0.896 |
| Impairment while working due to health | -24.62 ± 1.750 | -24.24 ± 1.735 |
| Overall work impairment due to health | -25.45 ± 1.922 | -24.14 ± 1.904 |
| Activity impairment due to health | -27.44 ± 1.530 | -24.89 ± 1.511 |
WPAI questionnaire measures impact due to poor health due to asthma on work and regular activities, yielding 4 percentage-based impairment scores, each ranges from 0 to 100%. Higher value=greater impairment and less productivity. Calculation of these 4 scores are as follows: 1. Work time missed due to health (Absenteeism) =hours missed due to health divided by (hours missed due to health+hours missed for other reasons+hours actually worked) \*100. 2. Impairment while working due to health (Presenteeism) =Question (Q)5 score (from 0 to 10) divided by 10\*100. 3. Overall work impairment due to health =Absenteeism+(1-Absenteeism fraction)\*Presenteeism. 4. Activity impairment due to health =Q6 score (from 0 to 10) divided by 10\*100. Baseline is last non-missing value prior to or on prescription date of study intervention.
Results for this outcome have not been posted.
FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Trough FEV1 on treatment is defined as the last FEV1 value obtained prior to the morning dose of investigational product. Spirometry was performed to assess FEV1. Baseline is defined as the last acceptable/borderline acceptable pre-dose FEV1 obtained at the Randomization Visit (Visit 2/Day 1). Per Protocol the study's subgroup analysis design, the analysis for this endpoint at Week 24 will be performed based on results from the composite (optimized) endpoint's Week 52 analysis. The pending results are expected to be available within 12 months of End of Study (EOS) date.
Results for this outcome have not been posted.
The ACQ-7 measures 7 attributes of asthma control \& includes 5 symptom questions (nocturnal awakening,symptoms on waking in morning,activity limitation,shortness of breath \& wheeze). Responses ranges from 0 (no impairment/limitation) to 6 (total impairment/ limitation). ACQ-7 total score is mean of the responses of 7 items, ranges from 0 to 6. Higher score = poor control. A score of \<= 0.75 is well-controlled asthma; a score between 0.75 and 1.5 is partially controlled asthma \& a score \>= 1.5 is poorly controlled asthma. \>= 0.5 point decrease from baseline is clinically important change in asthma control. Baseline is last non-missing value prior to or on the prescription date of study intervention. Per Protocol study's subgroup analysis design, analysis for this endpoint at Week 24 will be performed based on results from composite (optimized) endpoint's Week 52 analysis. The pending results are expected to be available within 12 months of EOS date.
Results for this outcome have not been posted.
The ACQ-7 measures 7 attributes of asthma control \& includes 5 symptom questions (nocturnal awakening,symptoms on waking in the morning,activity limitation,shortness of breath \& wheeze). Responses ranges from 0 (no impairment/limitation) to 6 (total impairment/ limitation). ACQ-7 total score is mean of the responses of the 7 items, ranges from 0 to 6. Higher score = poor control. A score of \<= 0.75 is well-controlled asthma; a score between 0.75 and 1.5 is partially controlled asthma \& a score \>= 1.5 is poorly controlled asthma. \>= 0.5 point decrease from baseline is clinically important change in asthma control. Baseline is last non-missing value prior to or on the prescription date of study intervention.
Results for this outcome have not been posted.
The ACQ-7 measures 7 attributes of asthma control and consists of 5 symptom related questions with response options ranging from 0 (no impairment/limitation) to 6 (total impairment/ limitation). ACQ-7 total score is mean of responses of the 7 items, ranges from 0 to 6. Higher score indicates poor control. A score of less than equal to 0.75 indicates well-controlled asthma, a score between 0.75 and 1.5 indicates partially controlled asthma, and a score \>=1.5 indicates poorly controlled asthma. Baseline is defined as last non-missing value prior to or on prescription date of study intervention. Per Protocol the study's subgroup analysis design, the analysis for this endpoint at Week 24 will be performed based on results from the composite (optimized) endpoint's Week 52 analysis. The pending results are expected to be available within 12 months of End of Study date.
Results for this outcome have not been posted.
The ACQ-7 measures 7 attributes of asthma control and consists of 5 symptom related questions (nocturnal awakening, symptoms on waking in the morning, activity limitation, shortness of breath, and wheeze) with response options ranging from 0 (no impairment/limitation) to 6 (total impairment/ limitation). ACQ-7 total score is the mean of the responses of the 7 items, ranges from 0 to 6. Higher score indicates poor control. A score of less than equal to 0.75 indicates well-controlled asthma, a score between 0.75 and 1.5 indicates partially controlled asthma, and a score \>=1.5 indicates poorly controlled asthma. Baseline is defined as the last non-missing value prior to or on the prescription date of study intervention.
Results for this outcome have not been posted.
FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Trough FEV1 on treatment is defined as the last FEV1 value obtained prior to the morning dose of investigational product. Spirometry was performed to assess FEV1. Baseline is defined as the last acceptable/borderline acceptable pre-dose FEV1 obtained at the Randomization Visit (Visit 2/Day 1). Per Protocol the study's subgroup analysis design, the analysis for this endpoint at Week 24 will be performed based on results from the composite (optimized) endpoint's Week 52 analysis. The pending results are expected to be available within 12 months of End of Study date.
Results for this outcome have not been posted.
The ACQ-7 measures 7 attributes of asthma control and consists of 5 symptom related questions (nocturnal awakening, symptoms on waking in the morning, activity limitation, shortness of breath and wheeze) with response options ranging from zero (no impairment/limitation) to 6 (total impairment/ limitation). A score of \<=0.75 indicates well-controlled asthma and a score \>=1.5 indicates poorly controlled asthma. \>= 0.5 point decrease from baseline is clinically important change in asthma control. Baseline is defined as the last non-missing value prior to or on the prescription date of study intervention. Per Protocol the study's subgroup analysis design, the analysis for this endpoint at Week 24 will be performed based on results from the composite (optimized) endpoint's Week 52 analysis. The pending results are expected to be available within 12 months of End of Study date.
Results for this outcome have not been posted.
The ACQ-7 measures 7 attributes of asthma control and consists of 5 symptom related questions (nocturnal awakening, symptoms on waking in the morning, activity limitation, shortness of breath and wheeze). Response ranges from 0 (no impairment/limitation) to 6 (total impairment/ limitation). ACQ-7 total score is mean of the responses of 7 items, ranges from 0 to 6. Higher score = poor control. A score of \<=0.75 indicates is well-controlled asthma; and a score \>=1.5 indicates poorly controlled asthma. Baseline is defined as the last non-missing value prior to or on the prescription date of study intervention.
Results for this outcome have not been posted.
The ACQ-7 measures 7 attributes of asthma control and consists of 5 symptom related questions (nocturnal awakening, symptoms on waking in the morning, activity limitation, shortness of breath and wheeze) with response options ranging from zero (no impairment/limitation) to 6 (total impairment/ limitation). A score of less than equal to 0.75 indicates well-controlled asthma, a score between 0.75 and 1.5 indicates partially controlled asthma, and a score \>=1.5 indicates poorly controlled asthma. A change of 0.5 in score suggests a clinically important change in asthma control. Baseline is defined as the last non-missing value prior to or on the prescription date of study intervention. Per Protocol the study's subgroup analysis design, the analysis for this endpoint at Week 24 will be performed based on results from the composite (optimized) endpoint's Week 52 analysis. The pending results are expected to be available within 12 months of End of Study date.
Results for this outcome have not been posted.
The ACQ-7 measures 7 attributes of asthma control and consists of 5 symptom related questions (nocturnal awakening, symptoms on waking in the morning, activity limitation, shortness of breath and wheeze) with response options ranging from zero (no impairment/limitation) to 6 (total impairment/ limitation). A score of less than equal to 0.75 indicates well-controlled asthma, a score of between 0.75 and 1.5 indicates partially controlled asthma, and a score \>=1.5 indicates poorly controlled asthma. Baseline is defined as the last non-missing value prior to or on the prescription date of study intervention.
Results for this outcome have not been posted.
Collected over All-cause mortality, serious adverse events (SAE) and non-serious study intervention related adverse events (AE) were collected up to Week 24. Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Fluticasone Furoate [FF]/ Umeclidinium [UMEC] / Vilanterol [VI] | 0/631 (0%) | 10/631 (1.6%) | 18/631 (2.9%) |
| Inhaled Corticosteroid [ICS]/Long-acting Beta-2 Agonist [LABA] | 1/605 (0.2%) | 7/605 (1.2%) | 4/605 (0.7%) |
| Event | Fluticasone Furoate [FF]/ Umeclidinium [UMEC] / Vilanterol [VI] | Inhaled Corticosteroid [ICS]/Long-acting Beta-2 Agonist [LABA] |
|---|---|---|
| AsthmaRespiratory, thoracic and mediastinal disorders | 2/631 | 1/605 |
| Acute respiratory failureRespiratory, thoracic and mediastinal disorders | 1/631 | 1/605 |
| PneumoniaInfections and infestations | 1/631 | 1/605 |
| Cervix carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/631 | 1/605 |
| Large intestine polypGastrointestinal disorders | 0/631 | 1/605 |
| Pancreatitis acuteGastrointestinal disorders | 0/631 | 1/605 |
| DeathGeneral disorders | 0/631 | 1/605 |
| Meniscus injuryInjury, poisoning and procedural complications | 0/631 | 1/605 |
| HypotensionVascular disorders | 0/631 | 1/605 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 1/631 | 0/605 |
| Event | Fluticasone Furoate [FF]/ Umeclidinium [UMEC] / Vilanterol [VI] | Inhaled Corticosteroid [ICS]/Long-acting Beta-2 Agonist [LABA] |
|---|---|---|
| DysphoniaRespiratory, thoracic and mediastinal disorders | 18/631 | 4/605 |
| Age, Continuous(YEARS) | Fluticasone Furoate [FF]/ Umeclidinium [UMEC] / Vilanterol [VI] | Inhaled Corticosteroid [ICS]/Long-acting Beta-2 Agonist [LABA] | Total |
|---|---|---|---|
| Mean | 48.3 ± 15 | 48.6 ± 15.25 | 48.5 ± 15.12 |
| Sex: Female, Male(Participants) | Fluticasone Furoate [FF]/ Umeclidinium [UMEC] / Vilanterol [VI] | Inhaled Corticosteroid [ICS]/Long-acting Beta-2 Agonist [LABA] | Total |
|---|---|---|---|
| Female | 467 | 452 | 919 |
| Male | 215 | 224 | 439 |
| Race/Ethnicity, Customized(Participants) | Fluticasone Furoate [FF]/ Umeclidinium [UMEC] / Vilanterol [VI] | Inhaled Corticosteroid [ICS]/Long-acting Beta-2 Agonist [LABA] | Total |
|---|---|---|---|
| American Indian or Alaska Native | 3 | 3 | 6 |
| Asian | 193 | 191 | 384 |
| White | 420 | 421 | 841 |
| Not Reported | 1 | 0 | 1 |
| Black or African American | 59 | 55 | 114 |
| Native Hawaiian or Other Pacific Islander | 4 | 2 | 6 |
| Multiple | 2 | 4 | 6 |
Showing the first 100 of 117 sites across 8 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers may request access to anonymized individual patient-level data (IPD) and related study documents of the eligible studies via the Data Sharing Portal. Details on GSK's data sharing criteria can be found at: https://www.gsk.com/en-gb/innovation/trials/data-transparency/
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.
Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.
Data sharing details ↗ · www.gsk.com
Ran from Apr 2024 to primary completion in Jul 2025, 15 months.
Results were first posted in Oct 2026, 1 year 2 months after primary completion.
Of 66 industry-sponsored phase 4 interventional studies under Asthma, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 33. This study's 15 months is below that.
Counting every sponsor, half of 156 studies reached it within 24 months; a quarter within 11 and three quarters within 37.
Completion moved once since we started tracking on Sep 25, 2026: Mar 2027 → Jun 2027, on Oct 6, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Fluticasone furoate · Umeclidinium bromide · Vilanterol trifenatate